Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes

By sjmartinez • March 5, 2025

Mariette X, Borchmann S, Aspeslagh S, Szekanecz Z, Charles-Schoeman C, Schreiber S, Choy EH, Peyrin-Biroulet L, Schmalzing M, Tanaka Y, Ten Cate H, Westhovens R, van der Woude CJ, Ekoka Omoruyi EV, Faes M, Masior T, Van Hoek P, Watson C, Rudolph C, Stallmach A. Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open. 2025 Mar 4;11(1):e005033. doi: 10.1136/rmdopen-2024-005033. PMID: 40037922; PMCID: PMC11881192.

Tags: Antirheumatic Agents, Arthritis, Inflammation, Publications, Rheumatoid, Rheumatology

Related Posts

Perceived Utility of Cognitive Behavioral Therapy in People With Bowel Disorders of Gut-Brain Interaction

Veraza DI, Waseem MR, Venezia J, Montero AM, Jones S, Kadariya J, Gupta A, Xu H, Shin A. Perceived Utility of Cognitive Behavioral Therapy in[...]

Escherichia coli ST131 Drives Carbapenem Use for E. Coli Bloodstream Infections

Mackow NA, Shao W, Ge L, Komarow L, Jiang J, Boutzoukas A, Chen L, Garcia-Diaz J, Herc ES, Doi Y, Arias CA, Albin O, Saade[...]

Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF

Ahmed AA, Lu F, Zhang S, Raman VK, Patel SS, Morgan CJ, Faselis C, Lam PH, Fonarow GC, Heidenreich PA, Ahmad T, Anker SD, Metra[...]